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ABSTRACT. PolyLactic and Glycolic Acid nanoparticles (PLGA-NPs), coated with L-Ferritin, 
are exploited for the simultaneous delivery of paclitaxel and an amphiphilic Gd based MRI 
contrast agent into breast cancer cells (MCF7). L-Ferritin has been covalently conjugated to the 
external surface of PLGA-NPs exploiting NHS activated carboxylic groups. The results 
confirmed that nanoparticles decorated with L-Ferritin have many advantages with respect both 
albumin-decorated and non-decorated particles. Ferritin moieties endow PLGA-NPs with 
targeting capability, exploiting SCARA5 receptors overexpressed by these tumour cells, that 
results in an increased paclitaxel cytotoxicity.  Moreover, protein coating increased nanoparticle 
stability thus reducing the fast and aspecific drug release before reaching the target. The 
theranostic potentiality of the nanoparticles has been demonstrated by evaluating the signal 
intensity enhancement on T1-weighted MRI images of labelled MCF7 cells. The results were 
compared with that obtained with MDA cells used as negative control due to their lower 
SCARA5 expression.   
 
 
 
 
 
Keywords. Polylactic and glycolic (PLGA) nanoparticles; Ferritin, Gd based contrast agents, 
MRI, Paclitaxel, breast cancer.  
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INTRODUCTION  
Nanotechnology is under intense scrutiny in the design of new medical protocols, as a significant 
improvement of diagnoses and therapy
1
, in particular of cancer and cardiovascular diseases, is 
expected from the application of nanosized drug delivery systems
2
. In this contest, liposomes, 
solid-lipid nanoparticles, and biodegradable polymeric nanoparticles are the most widely 
investigated systems. Poly (D, L-lactide-co-glicolide) (PLGA) has attracted great attention in the 
design of nanosized delivery systems because of its excellent biocompatibility and 
biodegradability, associated to the presence of ester linkages that undergo slow hydrolysis in 
aqueous system
3
. The removal of nanosized drug carriers from the body, due to their 
hydrophobic nature, by the Mononuclear Phagocyte System is a major obstacle that hinders the 
application of these drug delivery systems
4
. Therefore surface modification and coating of PLGA 
nanoparticles is the subject of studies aimed at prolonging their circulation lifetime. The most 
commonly used strategy to obtain stealth nanoparticles is based on the use of PEG and it has led 
to the development of several products that are currently in clinical use
5
. However, the recent 
observation of anti-PEG immunological response
6
 has motivated a renewed interest towards the 
research for alternative strategies. Among possible surface modification of PLGA nanoparticles, 
serum albumin has received some attention due to its relatively small size, hydrophilic surface 
and accumulation in leaky vasculature of tumours through passive targeting
7-9
. PLGA 
nanoparticles coated with serum albumin showed an improved stability and when loaded with 
the anti-tumoral paclitaxel drug, a more efficient delivery to tumour cells. Herein we report 
results concerning the use of Ferritin as alternative protein coating for PLGA surface. In addition 
to act as a hydrophilic cover, Ferritin may endow the nanoparticle with a potential targeting 
capability thus improving the uptake from the tumour cells through specific ferritin receptors. 
Ferritin is the main iron storage protein and is composed of 24 subunits of heavy (H)- or light 
(L)-chain polypeptides that are present at different ratios in various organs to form a cage 
architecture of 12 nm in external diameter, with an inner cavity of 8 nm
10
.
 
Ferritin functions are 
traditionally associated with intracellular iron storage but additional functions related to iron 
delivery based on a transferrin-independent mechanism to different target organs (such as brain, 
liver and spleen) have been recently discovered and investigated
11
. The involved receptors 
belong to scavenger receptor class A member 5 (SCARA5)
12-14
 for L-ferritin and to TIM-2
15
 and 
TfR-1
16, 17 
for H-ferritin, in mice and human, respectively. Based on evidence attained from both 
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epidemiological and molecular studies, new insights are linking the presence of excess iron and 
altered iron metabolism to cancer as a consequence of the rapid cell proliferation
18
. It is well 
known that, many cancer cells reprogram iron metabolism in ways that result in net iron influx
19
. 
This occurs through the up-regulation of the expression of proteins that are involved in iron 
uptake (i.e. TfR1, SCARA5) and the decreased expression of iron efflux proteins, such as 
ferroportin. The relationship between ferritin and cancer is well supported by studies showing an 
increase of the total ferritin (rich in L-chains) in the blood serum
20
. For example, in breast cancer 
patients, it was found a correlation with ferritin increase and the stage of the disease, as the high 
serum concentration of the protein is associated with the release within the breast tumor 
microenvironment
21
. Accordingly, breast tumor lysates also show elevated levels of L-ferritin, 
the predominant subunit observed in serum, and this increase correlates with advanced 
histological grade and poor outcome
22, 23
. There are many examples in the literature exploiting 
ferritin for the delivery of water soluble drugs and imaging agents loaded in its inner aqueous 
cavity
24-27
. In this context, we have previously reported that native horse spleen Ferritin 
(composed by 85% and 15% L and H chains, respectively) is selectively taken-up by the human 
breast cancer cell line MCF7 through SCARA5 receptors
28
. 
On this basis herein we propose the use of ferritin as simultaneous targeting and coating agent 
for PLGA nanoparticles, able to deliver selectively paclitaxel (PTX),  a cytostatic compound 
with very low water solubility, to breast cancer (MCF-7 cells). Horse spleen ferritin has been 
covalently conjugated to the external surface of PLGA nanoparticles exploiting NHS activated 
carboxylic groups (Figure 1A). Moreover, PLGA nanoparticles have been loaded with a Gd 
based MRI imaging agent (Gd-DOTAMA, Figure 1B), in order to monitor their distribution. The 
performance of ferritin functionalized PLGA nanoparticles has been compared with the 
corresponding albumin coated ones as well as with unfunctionalized particles. 
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Figure 1. A) Schematic representation of PLGA-Ferr nanoparticles; B) Schematic 
representation of Gd-DOTAMA.   
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RESULTS AND DISCUSSION 
Preparation of PLGA nanoparticles (PLGA-NPs) 
 
PLGA is one of the most attractive biodegradable and biocompatible polymer that has been used 
in a number of applications, ranging from drug delivery to tissue engineering
29
. PLGA 
nanoparticles are characterized by a hydrophobic core that enables entrapping water insoluble 
hydrophobic molecules. PLGA-NPs were obtained by the o/w emulsion solvent extraction 
method. The organic phase was prepared by dissolving PLGA or PLGA-NHS and Gd-
DOTAMA complex in chloroform
30
. The water phase was a poly vinyl alcohol (PVA) aqueous 
solution. PVA is the most commonly used emulsifier for the preparation of PLGA-based NPs 
because it yields particles that are relatively uniform, small sized, and easy to be re-dispersed in 
water
31
. The organic phase was added to the aqueous phase, and then the resulting mixture has 
been extensively sonicated. The nanoparticles were obtained by the slow organic solvent 
evaporation of the o/w emulsion. Then, ferritin (Horse Spleen Ferritin) or bovine serum albumin 
(BSA) were covalently conjugated to PLGA-NHS nanoparticles exploiting the reaction of 
PLGA–NHS with the amine groups present on the proteins external surface
32-34
. Before 
conjugation Ferritin was purified by gel filtration chromatography to eliminate high molecular 
weight aggregates whereas BSA was used without further purification. The reaction was carried 
out overnight, at room temperature, under magnetic stirring. Pure PLGA-Ferr and PLGA-BSA 
have been obtained after size exclusion chromatography (see supporting Information, Figure S1). 
Control nanoparticles (PLGA-CTRL), without protein coating, were synthesized following the 
same synthetic protocol using the commercially available PLGA with unconjugated carboxylic 
groups. As reported in Table 1 both the average PLGA hydrodynamic diameters (measured by 
dynamic light scattering) and the longitudinal relaxation rate of water protons (1/T1) of the 
conjugated nanoparticles were unaffected by the protein conjugation. The amount of Ferritin or 
BSA bound to PLGA-NPs after size exclusion chromatography purification was of 0.23±0,04 
and 0.21±0.03 mg/ml, respectively, which represent approximately 121±25 Ferritin and 763 ±83 
BSA molecules per NPs, respectively. Interestingly, one may observe that the ratio between the 
amount of Ferritin and BSA bound to PLGA-NPs corresponds approximately to the ratio of the 
molecular weights of the two proteins. In order to rule out the occurrence of a non-covalent 
adsorption of the proteins on the PLGA surface, as reported in literature for serum proteins
35,36
, 
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non-activated PLGA-CTRL were incubated overnight in the presence of the same amount of 
Ferritin and BSA. The obtained solutions were purified by gel filtration using the same protocol. 
In the solutions of purified nanoparticles the protein concentrations was in both cases under the 
detection limit (0.034mg/ml). The low absorption is the consequence of the lower albumin 
(BSA) concentration incubated (2 mg/ml) and the negative Z-potential of PLGA-CTRL (-
3.9±1.5). The number of GdDOTAMA loaded in one nanoparticle (ca. 1x10
5
) is of the same 
order of those reported for liposomes or other nanoparticles embedded with contrast agents in 
their interior and not only on their surface
37,38
. 
 
Table 1. Hydrodynamic particle diameter measured by DLS at 25°C in HBS Buffer and 
Polidispersity Index (PDI) of PLGA-CTRL, PLGA-Ferr and PLGA-BSA are reported together 
with their millimolar relaxivities (mM
−1
 s
−1
) and of Gd-DOTAMA and protein encapsulation 
yields. The table shows the mean ± SEM of 5 independent experiments 
 PLGA-CTRL PLGA-Ferr PLGA-BSA 
SIZE (nm) 152±8 157±9 154±14 
PDI 0.193±0.024 0.214±0.043 0.141±0.007 
r
1p
 (mM
-1
s
-1
) 26.6±1 29.3±0.93 29.7±0.3 
Gd-DOTAMA (%) 57±14 38±10 39±11 
Protein (%)  3.7±0.8 4.7±0.7 
Number of Proteins/NP  121 ±25 763±83 
Number of Gd/NP 1.0x10
5
±0.1x10
5
 1.3x10
5
±0.3x10
5
 1.0x10
5
±0.15x10
5
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Cellular Uptake of PLGA-Ferr and PLGA-BSA by human breast cancer cell lines. 
The uptake of PLGA-Ferr and PLGA-BSA was assessed in human breast cancer cells MCF-7 
and MDA-MB-231, respectively.  As already well established
28
, MCF7 express a relatively high 
concentration of SCARA5 receptors on their cytoplasmatic membrane, able to internalize L-
Ferritin, whereas MDA-MB-231 has been used as negative control
28
. Cells were incubated in the 
presence of PLGA-BSA and PLGA-Ferr for 6h at 37 °C and 5% CO2. The amount of Gd, as 
determined by ICP-MS, is taken as reporter of the extent of cell internalized PLGA 
nanoparticles. Figure 2A shows the amount of internalized Gd normalized to the total protein cell 
content. The values of internalized Gd were significantly higher for MCF-7 incubated in the 
presence of PLGA-Ferr than PLGA-BSA (p <0.0241). On the contrary, Gd uptake into MDA-
MB-231 cells was lower and not significantly different for the two types of nanoparticles (p 
<0.249). This is in agreement with the fact that these cells express lower SCARA5 receptors than 
MCF-7
28
. Furthermore, the specificity of the uptake was supported by carrying out a competition 
study in which the MCF7 cells were incubated  with PLGA-Ferr for 6h in the presence of an 
excess (75 folds) of native Ferritin. The Gd uptake, measured by ICP-MS, decreased for about 
80% as shown in Figure 2B.  
 
Figure 2. (A) ICP-MS determination of the intracellular Gd content of MCF7 and MDA-MB-231 
cells cultured for 6h with PLGA-Ferr and PLGA-BSA 50 µM in Gd. (B) Competition experiment 
on MCF7 cells. ICP-MS measurements of intracellular Gd were done with or without the 
addition of an excess (75 times) of native ferritin. Graphs show the mean ± SEM of internalized 
Gd moles every mg of total cell proteins from 3 independent experiments. 
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Magnetic Resonance Imaging (MRI)  
In order to assess whether Gd-labelled PLGA-NPs can generate a sufficient MRI contrast for 
targeted cells MCF7 and MDA-MB-231, T1-weighted MR images were acquired on cellular 
pellets obtained upon incubation with PLGA-Ferr and PLGA-BSA (50 µM of Gd), respectively. 
Figure 3A shows that MCF-7 incubated with PLGA-Ferr displayed markedly higher signal 
intensity when compared to untreated cells or treated with PLGA-BSA. Only small changes in 
signal intensity (SI) were observed in MDA-MB-231 cells incubated in the absence or in the 
presence of PLGA-Ferr and PLGA-BSA, respectively. The differences among the relaxation 
rates (s
-1
) (Figure 3B) measured on the cell pellets reflected the observed difference in PLGA-
Ferr uptake by MCF-7 and MDA-MB-231 as expected by their different expression of ferritin 
receptors. 
 
Figure 3. A) Representative T1-weighted spin echo image (acquired at 7T) of glass capillaries 
containing MCF7 (1, 2, 3) and MDA-MB-231 (4,5,6) cells incubated for 6 hours in the absence 
(1,4 controls) and in the presence of PLGA-BSA (2,5) and PLGA-Ferr (3,6). B) R1obs (s
-1
) 
measured on cell pellets using a saturation recovery sequence. The histogram shows the mean ± 
SD of R1obs from 3 independent experiments. 
 
Loading of Paclitaxel in PLGA-NPs.  
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In order to design a “theranostic” system containing both imaging and therapeutic agents, 
paclitaxel (PTX) has been added to the previously described PLGA-NPs. Paclitaxel is a drug 
largely used in the  treatment for various types of cancer, including ovarian cancer, breast cancer, 
non-small cell lung cancer and Kaposi's sarcoma
39
. PTX is characterized by a low solubility in 
water and it is administered to patients in a micellar formulation based on macrogolglycerol 
ricinoleate dissolved in ethanol
40, 41
. The preparation of PLGA-PTX nanoparticles was performed 
using the same procedure described above. PTX was dissolved in chloroform together with 
PLGA or PLGA-NHS and Gd-DOTAMA at an initial PTX amount corresponding to 10% w/w 
(with respect to PLGA). Then pre-formed PLGA nanoparticles were conjugated with the protein 
(Ferritin or BSA). The PTX encapsulation yields, determined by HPLC, were 6.88±0.98, 
9.95±1.5, and 27.9±16 (±SEM) for PLGA-PTX-BSA, PLGA-PTX-Ferr and PLGA-PTX-CTRL, 
respectively. The significantly lower values found after proteins conjugation with respect to the 
unfuctionalized PLGA-PTX-CTRL appears due to the fact that a not negligible amount of 
nanoparticles went lost during the HPLC purification procedure. In fact, the differences are 
significantly reduced if the PTX loading efficiency is expressed as Gd/PTX % (21±10, 23±14, 16 
± 3.8 ±SEM for PLGA-PTX-BSA, PLGA-PTX_Ferr, and PLGA-PTX_CTRL respectively). In 
vitro drug release from PLGA nanoparticles was evaluated at different intervals of time under 
dialysis in 1L PBS buffer, as shown in Figure 4. It appears evident that PTX is released more 
slowly from PLGA-PTX-Ferr and PLGA-PTX-BSA than from PLGA-PTX-CTRL (15 ± 3.4%, 
20±4.5% and 40 ± 2.25% within 6 h, respectively (±SEM).  
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Figure 4: In vitro drug release from PLGA-PTX-CTRL, PLGA-PTX-Ferr and PLGA-PTX-BSA 
evaluated at different time (6, 24, 48h) under dialysis in PBS at 37°C, pH=7.4.  Graphs show the 
mean ± SD of % PTX release obtained by 3 independent experiments. 
 
 
PTX release from nanoparticles depends on drug diffusion at the PLGA surface that, in turn, is 
affected by “bulk” erosion or swelling
42
. The PTX release behavior from the herein developed 
nanoparticles exhibited a biphasic pattern characterized by an initial rapid release during the first 
24 h, followed by a slower and continuous release. The high initial burst release can be attributed 
to the dissolution of PTX physically adhered at the surface or located at the first layers of the 
solid nanoparticles
40
. It is likely that the presence of Ferritin or BSA on the surface of PLGA-
NPs slowed down this burst release compared to PLGA-PTX-CTRL Furthermore, the presence 
of protein on the outside layer of NPs could slowdown diffusion of hydrophobic PTX to the 
outside medium, making release slower compared to NP without protein coating. Also, the 
increasing diffusional distance for PTX molecule may delay the drug release from the core of the 
NPs 
9,43-45
. 
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Toxicity test of PLGA-PTX nanoparticles 
Viability assays were performed on MCF-7, as they showed a good capability to take-up PLGA-
PTX-Ferr nanoparticles. Cells were incubated in the presence of PLGA-PTX_Ferr, PLGA-PTX-
BSA, PLGA-PTX-CTRL and a commercially available Paclitaxel formulation administered to 
human patients (Paclitaxel Kabi) at increasing concentrations for 6h and 24h (Figure 5A,B).  The 
range of concentrations of PTX corresponds to plasma levels of the drug achievable in humans
46
. 
As mentioned above, Paclitaxel Kabi is a water soluble paclitaxel formulation containing 
macroglycol ricinolate. In agreement with that previously reported by Esfandyari-Manesh and 
coworkers
7
, we found that the toxicity, herein evaluated by MTT assay, of PLGA coated with 
BSA and loaded with PTX (PLGA-PTX-BSA) is significantly higher than the one observed for 
the commercially available Paclitaxel Kabi and for the PTX loaded PLGA-PTX-CTRL. The 
observed behavior may be accounted for the presence of gp60 (albondin) receptor and caveolar 
transport as both systems are involved in the transendothelial cell transport of albumin
7
. The data 
reported in Figure 5 show that the cytotoxicity is further enhanced by using PLGA coated with 
Ferritin that targets tumor cell more efficiently via the up regulation of SCARA5 receptors. The 
percent viability of MCF-7 incubated for 6h with PLGA-Ferr, PLGA-BSA, PLGA-CTRL and 
Paclitaxel Kabi (all at a final PTX concentration 20 µM) were 56%, 83.5%, 89% and 97%, 
respectively (Figure 5).  
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Figure 5: Percentage of viability (measured with MTT assay) of MCF-7 after 6h (A) and 24h (B) 
of incubation at different concentration of PLGA-PTX-CTRL, PLGA-PTX-Ferr, PLGA-PTX-BSA 
and Paclitaxel Kabi. Graphs show the mean ± SEM of % viability evaluated on 3 independent 
experiments. 
The low toxicity of the commercial drug is very likely due to the short treatment time, only 6h, 
which does not lead to enough internalized drug to have detectable cytotoxic effect. In fact, 
several experiments are reported in the literature where the therapeutic treatment is continued for 
more than 24 hours
41
. While the percent viability of MCF-7 after 24h of incubation at 20µM of 
PTX with PLGA-PTX-Ferr, PLGA-PTX-CTRL, PLGA-PTX-BSA, and Paclitaxel Kabi were 
29%, 45%, 63% and 72% (Figure 5B). The cytotoxicity of nanoparticles not loaded with 
paclitaxel was evaluated (see supplementary information, Figure S4) and it was less than 10% 
for all the PLGA-NPs after 6 and 24h incubation. Nanoparticles with or without PTX were 
incubated with cells at the same Gd concentration.  In order to prove the selective toxic effect of 
PLGA-PTX-Ferr for tumor cells a comparative cytotoxicity study was done on the human 
mammary non-tumorigenic epithelial cell line MCF-10A using the same protocol described 
above. Figure 6 shows clearly that PLGA-PTX-Ferr are significantly more toxic for tumor cells 
(MCF7) than healthy MCF-10A after 6 and 24h incubation. From these results one draws the 
conclusion that the specific uptake of PLGA-PTX-Ferr by breast cancer cells (MCF7) allows to 
increase the therapeutic output of PTX thus overcoming some limitation currently encountered in 
the clinical use of this drug. Indeed, despite of a wide spectrum of antitumor activity of PTX, its 
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therapeutic application in cancer therapy is still hampered by its low aqueous solubility (that 
necessitates the use of Cremophor ® EL, a noninonic solubiliser and emulsifier where the main 
component is glycerol polyethylene glycol ricinolate) and poor accumulation at the target tumor 
cells 
38, 39
. 
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Figure 6. Percentage of viability of MCF-7 and MCF-10A after 6h and 24h of incubation at 
different concentration of PLGA-PTX-Ferr. Graphs show the mean ± SEM of % viability 
evaluated on 3 independent experiments. 
 
CONCLUSIONS  
In this work it has been shown that the novel drug delivery system based on hydrophobic PLGA 
nanoparticles decorated with Ferritin has many advantages with respect non decorated particles. 
Ferritin moieties endow the PLGA-NPs with a targeting capability that, in turn, results in an 
increased cytotoxicity. Although we have considered only the aggressive breast cancer 
represented by MCF-7 cell line, it is reasonable to expect that similar results could be obtained 
from any tumour whose cells overexpress Ferritin transporters. Moreover, protein coating 
increases the stability of the nanoparticle thus avoiding the fast and aspecific drug release before 
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reaching the target.  Finally, the versatility of the PLGA nanoparticles permits the combination 
of therapy and diagnosis by entrapping MRI contrast agents inside the PLGA-NPs hydrophobic 
core, in a single drug delivery system. 
 
EXPERIMENTAL PROCEDURES 
Materials 
Poly (D,L-lactide-co-glicolide) (PLGA) RG 502H 50:50, molecular weight (MW) 30 000–60 
000 Da, and poly(vinyl alcohol) (PVA), MW 31 000–50 000 Da (98%–99%hydrolyzed), Ferritin 
from equine spleen (Ferr), Albumin from bovine serum (BSA), insulin, Thiazoly Blue 
Tetrazolium Bromide (MTT), N-ethyl-N′-(3- (dimethylamino)propyl) carbodiimide (EDC), N-
hydroxysuccinimide (NHS) and acetonitrile were provided by Sigma-Aldrich. Paclitaxel (PTX) 
was purchased from Aurisco Pharmaceutical Limited (China), while the Paclitaxel Kabi from 
Fresenius Kabi AG (Italy). The lipophilic Gd-DOTAMA (Figure 1B was synthesized according 
to a previously reported procedure
45
. Human breast cancer cell lines (MDA-MB-231 and MCF-
7) were obtained from ATCC. DMEM and EMEM media, Fetal Bovine Serum (FBS), penicillin, 
streptomycin, L-glutamine, non-essential amino acid, sodium pyruvate, and MycoAlert™ PLUS 
Mycoplasma Detection Kit, were obtained from Lonza (Belgium).  
Synthesis of N–hydroxysuccinimide activated PLGA (PLGA-NHS).  
PLGA polymer (100 mg, 0.0025mmol) was dissolved in CH3CN (1 ml). EDC (20 mg, 0.1 mmol) 
and NHS (10 mg, 0.09 mmol), both dissolved in CH3CN (0.5 ml) were subsequently added, to 
PLGA solution. The reaction was left to stir at room temperature for 12 h. The product was 
precipitated in diethyl ether and washed several times with diethyl ether/methanol (1:1) and dried 
under vacuum. The 
13
C-NMR (600 MHz, CDCl3) was used to assess the formation of the NHS 
ester (Figure S2 in Supporting Information). The disappearance of the carboxyl groups at 174.2 
and 171.8 ppm, corresponding to the PLGA carboxylic acid groups, proved the formation of 
NHS ester.  
Preparation of PLGA-NPs 
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PLGA-NPs were obtained using an oil-in-water (o/w) emulsion solvent extraction method. The 
emulsion was prepared by dissolving 25 mg of PLGA-NHS, 3.5 mg of Gd-DOTAMA in 0.5 ml 
of chloroform; this solution was called phase 1. Phase 2 consisted of 3% w/v PVA aqueous 
solution (3 ml). Phase 1 was added into phase 2 drop by drop and sonicated with a sonicator tip 
for 300 s at 100% power. Final emulsion was transferred to a 50 ml round-bottomed flask and 
put into a rotary evaporator at 740 mmHg and 30 rpm for 120 min to remove the organic solvent. 
Purification of Ferritin  
1 ml of commercial Ferritin was purified to eliminate its high molecular weight aggregates by 
size exclusion chromatography, using an AKTA FPLC Purifier system, equipped with UV–Vis 
detector (set at 215, 280, and 350 nm). Superose 6 10/300 GL was used as column and HBS 
buffer (1.8 mM Hepes and 150 mM NaCl, pH 7.4) as eluent at a flow rate of 0.5 mL min
-1
. The 
fraction which corresponded to ferritin monomer (440 KDa, VR = 13.2 ml) were collected and 
concentrated with vivaspin filters (Sartorius) (MWCO 10000 Da). The final concentration of 
protein was determined by means of the Bradford assay, using bovine serum albumin as a 
standard.   
Conjugation of Ferritin or Bovine Serum Albumin (BSA) to PLGA-NPs  
A solution of BSA or Ferritin in PBS (10 mg/ml) was added to PLGA-NPs solution immediately 
after nanoparticles preparation using a PLGA/protein ratio of 2.5:1 (25mg/10mg). The 
conjugation reaction between protein and PLGA-NPs was carried out at room temperature 
overnight under magnetic stirring. The reaction solution was centrifuged at 5000 rpm for 10 min 
and then purified by size exclusion chromatography using the same purification protocol used for 
ferritin. Chromatograms before and after purification are reported as supporting Information 
(Figure S1). The collected fractions corresponding to conjugated PLGA-NPs (VR =6.5 ml) were 
concentrated with vivaspin filters (Sartorius) (MWCO 10000 Da) by centrifugation at 5000 rpm. 
The amount of Gd-DOTAMA entrapped in the PLGA-NPs was determined by using inductively 
coupled plasma mass spectrometry (ICP-MS; element-2; Thermo-Finnigan, Rodano (MI), Italy). 
Sample digestion was performed with concentrated HNO3 (70%, 1 ml) under microwave heating 
(Milestone MicroSYNTH Microwave labstation). The hydrated mean diameter of conjugated 
PLGA-NPs were determined using a dynamic light scattering (DLS) Malvern Zetasizer 3000HS 
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(Malvern, U.K.) All samples were analyzed at 25 °C in filtered (cutoff, 200 nm) NaCl 10mM 
buffer (pH 7.4). The relaxivity (r1p) at 21.5 MHz and 25 °C was determined by 
1
H nuclear 
magnetic resonance T1 measurement (Stelar Spinmaster, Mede, Italy) by means of the inversion 
recovery method (16 delays values, two averages). The reproducibility of the T1 data was ±5%. 
The amount of conjugated proteins was determined by means of the Bradford assay, using 
bovine serum albumin as a standard. The average number of BSA or ferritin molecules 
conjugated to PLGA-NP was calculated by dividing the number of BSA or Ferritin molecules 
found in the solution (calculated from their final concentration) for the calculated average 
number (n) of PLGA-NPs. The average number (n) of PLGA-NPs was calculated using the 
following equation: 
( )ρπ ⋅⋅= 3/6 Dmn                     Equation 1 
where m is the NP weight, D is the number based on mean NP diameter determined by dynamic 
light scattering (DLS) and ρ is the NP weight per volume unit (density), estimated to be 1.1 
g/cm
3
 based on the polymer density
46
. The NP weight (m) was indirectly determined by the 
GdDOTAMA concentration considering than about 8 mg of GdDOTAMA are loaded into 100 
mg of PLGA nanoparticles as estimated by three independent PLGA-NPs preparations, purified 
by dialysis without centrifugation that causes nanoparticles aggregation and loss.    
Cell lines 
MDA-MB-231 cells were cultured in DMEM medium containing 10% (v/v) fetal bovine serum 
(FBS), 100 U/ml penicillin, 100 U/ml streptomycin, 0.01% and 4 mM L-glutamine. MCF-7 cells 
were cultured in EMEM medium containing 10% (v/v) FBS, 100 U/ml penicillin and 
streptomycin, 1% (v/v) non-essential amino acid, 1 mM sodium pyruvate, 2 mM L-glutamine, 
and 0.01 mg/ml
 
insulin. The MCF 10A cells were cultured in Dulbecco's modified Eagle's 
medium and Ham's F12 medium supplemented with 20 ng/ml epidermal growth factor, 100 
ng/ml cholera toxin, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone and 5% of horse serum. Cells 
were incubated at 37°C under a humidified atmosphere of 5% CO2. These cell lines were tested 
for mycoplasma (MycoAlert™ PLUS Mycoplasma Detection Kit, Lonza).  
Uptake experiments  
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For PLGA-BSA and PLGA-Ferr uptake experiments, MCF-7 and MDA-MB-231 were seeded at 
a density of 5 × 10
5
 cells in dishes of 6 cm Ø and placed in a wet (37 °C) 5% CO2 air atmosphere 
incubator. For the different experiments, at 48 h post seeding, cells were incubated with 50µM of 
Gd. After 6h of incubation, cells were washed three times with 10 ml ice-cold PBS, detached 
with trypsin/EDTA. The Gd content in each cell line was determined by ICP-MS. For MRI 
analysis (see below) cells were transferred into glass capillaries. Protein concentration 
(proportional to the cell number) was determined from cell lysates by the Bradford assay. 
MRI  
All the MR images were acquired on a Bruker Avance 300 spectrometer (7T) equipped with a 
Micro 2.5 microimaging probe (Bruker BioSpin, Ettlingen, Germany).Glass capillaries 
containing about 2 × 10
6
 cells were placed in an agar phantom and MR imaging was performed 
by using a standard T1-weighted multislice spin-echo sequence (TR/TE/ NEX = 250/3.7/8, FOV 
= 1.2 cm, MTX= 128x128, NEX = number of excitations; FOV = field of view). The T1 
relaxation times were calculated using a standard saturation recovery spin echo.  
Preparation and characterization of PTX loaded PLGA-NPs 
Targeted PLGA-NPs loaded with Paclitaxel were obtained using an oil-in-water (o/w) emulsion 
solvent extraction method. Briefly, 25 mg of PLGA-NHS, 2.5 mg of PTX and 3.5 mg of Gd-
DOTAMA were dissolved in chloroform and the same synthesis procedure described above was 
followed. Conjugation of ferritin or BSA to PTX loaded PLGA-NPs (PLGA-PTX-NP) was done 
following the procedure described above. The drug loading efficiency was determined in 
duplicate by HPLC on Waters Alliance-HPLC system equipped with 2695-separation module 
connected to 2998-photo diode array. A reverse phase Waters XBridge C18, 150 mm × 4.6 mm 
ID, 5 μm at 25°C was used as column. The water-acetonitrile was used as the mobile phase in 
gradient elution mode (acetonitrile: 0–2 min, 40%, 2-10 min, 40-100%). The effluent was 
monitored at 227 nm and flow rate was 1 mL/min. The retention time (Tr) of PTX was found to 
be 6.12 min. The PTX stock solution (1 mg/ml), dissolved in acetonitrile was diluted to the range 
10 μg/ml to 150 μg/ml for standard calibration curve (R
2
= 0.99984). 30µl of PLGA-PTX-NPs 
samples before injection were freeze-dried and then were sonicated in an ultrasonic bath in 200µl 
chloroform for 30 min. After centrifugation at 5000 rpm for 10 min and evaporation of the 
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chloroform, they were sonicated again with 200 µl acetonitrile for 15 min and then analyzed by 
HPLC injectin 50µl of samples. (Supporting Information, Figure S3) The encapsulation 
efficiency was defined by the ratio of the measured and initial amount of PTX encapsulated in 
the nanoparticles. 
 
In vitro drug release 
PTX-loaded nanoparticles, dissolved in HBS at a PTX concentration of 57 µg/ml were 
transferred to dialysis bags (MWCO 10 000 Da) and placed in 1L of HBS with stirring at 110 
rpm and 37 °C. At determined time intervals (6, 24 and 48 h), 30 µL of PLGA-PTX-Ferr and 
PLGA-PTX-BSA were taken and freeze-dried. Then the obtained powder was dissolved in 200 
µL of chloroform by sonicating in an ultrasonic bath for 30 min. After centrifugation at 5000 
rpm for 10 min and chloroform evaporation, the obtained powders were dissolved in 200 µL of 
acetonitrile, sonicated in an ultrasonic bath for 15 min and then analyzed by HPLC, as described 
above. 
In vitro cellular viability.  
MTT test (Sigma Aldrich) was used to evaluate the in vitro cytotoxicity of PLGA-PTX-Ferr and 
PLGA -PTX-BSA on MCF-7.  MCF-7 cells were seeded at density of 1 x 10
4 
viable cells /well in 
96-well plates 48h before experiments. Cells were incubated for 6h at increasing concentrations 
of nanoparticles ranging from 0 to 20µM PTX concentration. After a washing step with 100 µL 
phosphate buffer, 10 µL of MTT (5mg/ml in phosphate buffered saline (PBS): NaCl 0.136M, 
KCl 2.7mM, K2HPO4 8.6mM, KH2PO4 1.5mM) was added at 100 µL of medium. After 4h of 
incubation, the culture medium containing MTT solution was eliminated and crystals of 
formazan were dissolved in 150 µL of dimethyl sulfoxide (DMSO). Then micro plate reader 
(iMark 
TM
, BioRad) was used to read it at 570 nm wavelength. The effect of treatment was 
calculated as a percentage of viability against the controls.  
Statistical Analysis.  
Data were expressed as means ± SEM (standard error of the mean) or ± SD (standard deviation 
of the mean), as indicated in the different determinations, calculated from at least 3 independent 
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experiments. Statistical analyses were performed using the Student two-tailed t test. A p value 
less than 0.05 was considered statistically significant. 
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Figure 1. A) Schematic representation of PLGA-NPs-Ferr nanoparticles; B) Schematic representation of Gd-
DOTAMA.    
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Figure2. (A) ICP-MS determination of the intracellular Gd content of MCF7 and MDA-MB-231 cells cultured 
for 6h with PLGA-Ferr and PLGA-BSA 50 µM in Gd. (B) Competition experiment on MCF7 cells. ICP-MS 
measurements of intracellular Gd were done with or without the addition of an excess (75 times) of native 
ferritin. Graphs show the mean ± SEM of internalized Gd moles every mg of total cell proteins from 3 
independent experiments.  
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Figure 3. A) Representative T1-weighted spin echo image (acquired at 7T) of glass capillaries containing 
MCF7 (1, 2, 3) and MDA-MB-231 (4,5,6) cells incubated for 6 hours in the absence (1,4 controls) and in the 
presence of PLGA-BSA (2,5) and PLGA-Ferr (3,6). B) R1obs (s-1) measured on cell pellets using a saturation 
recovery sequence. The histogram shows the mean ± SD of R1obs from 3 independent experiments.  
 
254x190mm (96 x 96 DPI)  
 
 
Page 29 of 32
ACS Paragon Plus Environment
Bioconjugate Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
Figure 4: In vitro drug release from PLGA-PTX-CTRL, PLGA-PTX-Ferr and PLGA-PTX-BSA evaluated at 
different time (6, 24, 48h) under dialysis in PBS at 37°C, pH=7.4.  Graphs show the mean ± SD of % PTX 
release obtained by 3 independent experiments.  
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Figure5. Percentage of viability (measured with MTT assay) of MCF-7 after 6h (A) and 24h (B) of incubation 
at different concentration of PLGA-PTX-CTRL, PLGA-PTX-Ferr, PLGA-PTX-BSA and Paclitaxel Kabi. Graphs 
show the mean ± SEM of % viability evaluated on 3 independent experiments.  
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Figure 6. Percentage of viability of MCF-7 and MCF-10A after 6h and 24h of incubation at different 
concentration of PLGA-PTX-Ferr. Graphs show the mean ± SEM of % viability evaluated on 3 independent 
experiments.  
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